Professional Documents
Culture Documents
ValueResearchFundcard TataIndiaPharma&HealthCareFund DirectPlan 2019oct02
ValueResearchFundcard TataIndiaPharma&HealthCareFund DirectPlan 2019oct02
ValueResearchFundcard TataIndiaPharma&HealthCareFund DirectPlan 2019oct02
The contents of this Value Research Fund Card (the "Fund Card") published by Value Research India Private Limited are not intended to serve as professional advice
or guidance and the publisher takes no responsibility or liability, express or implied, whatsoever for any investment decisions made or taken by the readers of this
Fund Card based on its contents thereof. You are strongly advised to verify the contents before taking any investment or other decision based on the contents of this
Fund Card. The Fund Card is meant for general reading purposes only and is not meant to serve as a professional guide for investors. The readers of this Fund Card
should exercise due caution and/or seek independent professional advice before entering into any commercial or business relationship or making any investment deci-
sion or entering into any financial obligation based on any information, statement or opinion which is contained, provided or expressed in this Fund Card.
The Fund Card contains information, statements, opinions, statistics and materials that have been obtained from sources believed to be reliable and the publishers
of the Fund Card have made best efforts to avoid any errors and omissions, however the publishers of this Fund Card make no guarantees and warranties whatso-
ever, express or implied, regarding the timeliness, completeness, accuracy, adequacy, fullness, functionality and/or reliability of the information, statistics, statements,
opinions and materials contained and/or expressed in this Fund Card or of the results obtained, direct or consequential, from the use of such information, statistics,
statements, opinions and materials. The publishers of this Fund Card do not certify and/or endorse any opinions contained, provided, published or expressed in this
Fund Card. All disputes shall be subject to the jurisdiction of Delhi courts only.
Tata India Pharma & HealthCare Fund - Direct Plan
Rating: Not Rated Fund Performance Vs S&P BSE Healthcare TRI
Risk: Not Rated
Return: Not Rated
Fund
S&P BSE Healthcare TRI
(Rebased to 10,000)
History 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
NAV (Rs) - - - - - - 10.03 8.71 9.27 9.19 9.32
Total Return (%) - - - - - - - -13.15 6.36 -0.80 1.38
+/- S&P BSE Healthcare TRI - - - - - - - -0.72 5.26 4.55 11.97
+/- S&P BSE Sensex - - - - - - - -15.10 -21.55 -6.67 -4.82
Rank (Fund/Category) - - - - - - - 4/4 3/4 2/4 1/7
52 Week High (Rs) - - - - - - - 10.13 9.67 10.34 9.81
52 Week Low (Rs) - - - - - - - 8.43 8.12 8.23 8.90
Net Assets (Rs.Cr) - - - - - - 2.83 84.28 112.01 181.96 172.61
Expense Ratio (%) - - - - - - - 1.42 1.47 1.14 -
Sun Pharmaceutical Inds. Healthcare 105.50 -10.24 12.50 2019 4.61 -4.30 2.17 - -
Dr. Reddy's Lab Healthcare 30.00 2.79 11.35 2018 -6.44 2.93 7.30 -3.99 -0.80
Divi's Laboratories Healthcare 33.10 9.47 9.71 2017 6.90 -4.11 -5.72 10.05 6.36
Lupin Healthcare 20.80 -16.84 9.27 2016 -6.15 0.09 2.42 -9.73 -13.15
Ipca Laboratories Healthcare 21.90 11.33 8.34 2005 - - - - -
Abbott India Healthcare 46.40 44.41 8.01
Procter & Gamble Health Healthcare 55.80 47.34 6.37 Trailing Returns (%)
Aurobindo Pharma Healthcare 21.10 -21.10 5.90 Return Rank S&P BSE SIP
Healthcare
Sanofi India Healthcare 34.80 -8.14 4.57 Fund Category Fund/Cat TRI Return
Apollo Hospitals Healthcare 60.40 8.83 4.49 Year-to-Date 1.38 -4.42 1/7 -10.59 -
Alembic Pharmaceuticals Healthcare 14.70 -13.56 4.29 3-Month -0.04 -1.75 1/8 -4.54 0.05
Alkem Laboratories Healthcare 25.80 0.08 3.99 6-Month -3.58 -6.92 2/8 -13.92 -3.47
Cadila Healthcare Healthcare 17.40 -32.63 2.91 1-Year -2.91 -9.39 1/6 -17.32 -0.86
Dishman Carbogen Amcis Healthcare 49.50 -28.67 2.61 2-Year 5.18 0.68 1/4 -3.64 0.95
Healthcare Global Healthcare 513.00 -46.47 1.48 3-Year -1.16 -3.82 2/4 -7.99 1.22
5-Year - - - - -
7-Year - - - - -
10-Year - - - - -
Return less than 1-year are absolute and over 1 year are annualised
24733
Portfolio P/B Ratio 3.00 Equity 95.79
Portfolio P/E Ratio 26.39 Debt 0.00
3Y Earnings Growth (%) -0.76 Cash 4.21
Returns as on October 1, 2019, Portfolio related data as on August 31, 2019
Best Performance Value Research Analysis Fund Objective & Strategy
YEAR 24.71%
Analysis not available The scheme seeks long term
capital appreciation by
investing atleast 80% of it's
net assets in equity/equity
related instruments of the
companies in the pharma &
healthcare sectors in India.
QUARTER 22.79%
MONTH 10.52%
Portfolio Manager
Meeta Shetty
Worst Performance Since Nov 2018
YEAR -17.32%
Sailesh Jain
Since Nov 2018
QUARTER -14.24%
MONTH -11.93%
Investment Information
AMC : Tata Asset Management Private Ltd Min Investment (Rs.) : 5000
Website : www.tatamutualfund.com Min SIP Investment (Rs.) : 500
Registrar : Computer Age Management Services Ltd. Exit Load : 0.25% for redemption within 91 days
Launch : December 2015
Benchmark : S&P BSE Healthcare TRI
All the graphs are rebased to 10,000 Plans (NAV) : Dividend (9.32) , Growth (9.32)
History
Fund Performance Vs Index
Data on the fund’s performance Sample Mutual Fund
since its launch. Graph of how an investors’ money
Rating: Fund Performance Vs S&P CNX Nifty
z NAV (Year End) — The last Risk: Low 90000
would have grown in the fund since
NAV of each year. Return: Above Average its launch. A similar graph of the
70000
z Total Return — The percent- Fund
fund’s benchmark index is also
age returns that an investor S&P CNX Nifty
50000
given. For ease of comparison,
would have got over the (Rebased to 10,000) 30000 both have been adjusted to start at
year. 10000
10,000.
z +/- — In the given year, a History 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
comparison of the fund’s NAV (Rs) - - - - 10.33 19.71 23.94 33.94 50.13 81.34 41.89
Total Return (%) - - - - - 90.80 21.46 41.77 47.70 62.26 -48.50
returns with that of two stock +/-S&P CNX Nifty (%) - - - - - 18.90 10.78 5.43 7.87 7.49 3.29
market indices +/-BSE 200 (%) - - - - - -3.67 5.77 7.97 8.12 1.82 7.96
Rank (Fund/Category) - - - - - 54/70 50/79 65/101 27/145 71/162 34/192
z Rank — The fund’s perform- 52 Week High (Rs) - - - - 10.33 19.71 23.94 33.94 50.76 81.46 83.52
ance rank within its category 52 Week Low (Rs) - - - - 8.84 9.91 16.36 22.34 32.26 46.06 36.49
z 52-Week NAV Range — The Bharti Airtel Communication 18.56 -28.10 6.49 2008 -24.24 -14.18 -2.23 -18.97 -48.50 The funds’ returns over each quar-
highest and the lowest NAV
Reliance Industries
ONGC
Energy
Energy
11.50
8.31
-57.30
-46.00
5.42
4.50
2007
2006
-1.42
19.42
14.53
-7.25
16.01
19.39
23.88
11.70
62.26
47.70
ter of the last five years, along with
that the fund recorded dur- HDFC Bank Financial 20.67 -42.26 3.93 2005 -0.04 6.52 23.26 8.02 41.77 the entire year’s returns.
HDFC Financial 17.10 -48.21 3.51 2004 0.71 -13.50 15.08 21.15 21.46
ing that year Satyam Computer Services Technology 7.86 -62.12 3.16
Trailing Returns (%)
z Net Assets — The total
ITC FMCG 21.00 -18.47 2.72
Axis Bank Financial 10.42 -47.82 2.70 Return Rank S&P SIP
amount of investor’s assets Infosys Technologies Technology 14.29 -36.79 2.64 Fund Category Fund/Cat CNX Nifty Return
United Spirits FMCG 23.26 -55.48 2.34
that the fund was managing
Year-to-Date -48.50 -55.29 34/192 -51.79 -40.18
ICICI Bank Financial 9.49 -63.62 2.26 3-Month -18.97 -22.88 41/213 -24.53 -0.86
at the end of the year. Dr. Reddy's Lab
State Bank of India
Health Care
Financial
13.61
9.39
-36.12
-45.67
2.19
2.13
6-Month -20.78 -27.09 38/209 -26.76 -33.43
Trailing Returns (%)
1-Year -48.50 -55.29 34/192 -51.79 -40.18
z Expense Ratio — The per- Crompton Greaves Engineering 12.29 -65.84 2.12 2-Year -8.59 -16.06 22/158 -13.63 -24.19